Fuyuan Pharmaceutical has recently been granted the Drug Registration Certificate for its Lansoprazole Enteric-coated Capsules, available in 15mg and 30mg specifications, by the National Medical Products Administration. This approval signifies the successful completion of the consistency evaluation for the drug, marking a significant milestone for Fuyuan. The addition of this product to the company's portfolio is expected to further diversify its offerings and bolster its competitive edge in the market. To date, Fuyuan has invested a total of RMB 5.8323 million in the research and development of Lansoprazole Enteric-coated Capsules.